Overview
We study how cancer cells adapt to therapy and evade immune control in solid tumors, with a focus on prostate and bladder cancer. Our work integrates functional genomics, clinical data, and epigenetic analysis to uncover mechanisms of disease progression and identify new therapeutic opportunities.
Tumor intrinsic programs
What are the core regulatory programs that sustain cancer cell growth and resistance?
We use CRISPR based functional genomics and clinical datasets to identify key regulators of oncogenic signaling, including androgen receptor activity and epigenetic states such as CpG methylation. These studies define mechanisms of aggressive disease and nominate targets for biomarker development and therapeutic intervention.
Tumor immune interactions
Why do solid tumors resist immune attack, and how can this be overcome?
We study how tumor intrinsic pathways shape immune evasion using CRISPR screening in co-culture systems, organoids, and in vivo models. Our goal is to identify mechanisms that limit immune recognition and function, discover new immune checkpoints, and develop strategies to improve cellular therapies, including CAR T and CAR NK approaches.